A non-injectable vaccine patch can fight different variants of COVID-19, such as Omicron and Delta, better than traditional vaccines according to University of Queensland research in mice.
The research, conducted in collaboration with Brisbane Biotechnology Company Vaxxas, tested the Hexapro SARS-CoV-2 chicken. prevention using the Vaxxas high-density microarray patch (HD-MAP) technology, and the results found that the patch was more effective in eliminating the variants of COVID-19.
UQ’s Dr Christopher McMillan said the vaccine patch appeared to treat the new variant more effectively than the current SARS-CoV-2 vaccine given by injection.
“The advanced microneedling system is a vaccine delivery platform that delivers the vaccine precisely in the areas of the skin that are rich in it. AntibioticsDr. McMillan said.
“We found that the vaccine by patch was almost 11 times more effective in fighting the Omicron variant compared to the vaccine given by injection.”
He said the results went further than just injecting Hexapro.
“So far, all types of vaccines we’ve tested by patch, including subunit, DNA, inactivated viruses and conjugates produce better immune responses compared to traditional vaccine methods,” he said. hear it.
Dr. UQ’s David Muller said current vaccines would be ineffective because of new variants of COVID-19 emerging regularly, leaving researchers at a critical juncture.
“The Omicron variant explains this reduced effect, which contains more than 30 mutations in the spike protein,” said Dr. Muller.
“Several mutations have enabled the virus to evade the immune response induced by current vaccines.
“However, patch technology has the potential to offer a new—and more effective—weapon in our arsenal, at a time when new variants are evolving rapidly.
“The exercises are not only more effective against developing differences but are also easier to administer than injections.
“However, it is important to emphasize that the existing vaccines are still an effective way to fight serious diseases and infections from this virus and it is not time to abandon our system.”
Vaxxas CEO David Hoey said this is further evidence of a potential game changer technology platform it can better help communities to deal with global health problems, such as current and future epidemics.
“We continue to improve the capacity of our factories and increase our growth product development in preparation for major clinical trials,” he said.
“This includes building our first manufacturing facility in Brisbane to support the commercialization of our HD-MAP vaccine candidates, including Hexapro COVID-19. patch.”
The study was published in Vaccination.
Christopher LD McMillan et al, Skin-patch-administered antibiotics induce multiple antibody responses against SARS-CoV-2 strain variants, Vaccination (2022). DOI: 10.1016/j.vaccine.2022.07.013
The one who gave
University of Queensland
hint: COVID vaccine patch fights variants more than needles (2022, July 28) Retrieved July 28, 2022 from https://medicalxpress.com/news/2022-07-covid-vaccine-patch-variants-needles. html
This document is subject to copyright. Except for any bona fide transaction for research or investigation purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.
COVID vaccine patch fights variants better than needles Source link COVID vaccine patch fights variants better than needles